Transgene S.A.
TNG
Rangering i aksjer
#17440
Transgene SA, a French biotechnology firm headquartered in... Transgene SA, a French biotechnology firm headquartered in Illkirch-Graffenstaden, specializes in designing and developing groundbreaking therapeutic vaccines and oncolytic viruses to combat cancer and infectious diseases. Founded in 1979 and operating as a subsidiary of TSGH SAS, the company maintains a robust pipeline of treatments. This includes TG4050, a therapeutic vaccine in Phase I clinical trials for ovarian cancer and HPV-negative head and neck cancers, and TG4001, another therapeutic vaccine currently in Phase II for HPV-positive cancers. Its oncolytic virus programs feature TG6002, undergoing Phase I/IIa trials for various solid tumors, specifically gastrointestinal adenocarcinomas impacting the stomach, pancreas, and colon, as well as BT-001, an oncolytic virus in Phase I/II for solid tumors. Furthermore, Transgene is progressing TG1050, a therapeutic vaccine for chronic hepatitis B, and Pexa-Vec, an oncolytic virus targeting solid tumors. The company has established a comprehensive network of partnerships, encompassing strategic collaborations with major players like AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation, alongside licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva, and additional agreements with Sanofi, BioInvent, and Randox.
Aksjekurs
$0.82437785
Markedsverdi
$229.39M
Endring (1 dag)
1.02%
Endring (1 år)
-45.19%
Land
FR
Handel Transgene S.A. (TNG)
Kategori
Healthcare
Markedsverdi av Transgene S.A.(TNG)
Markedsverdi: $229.39M
Per October 2026 har Transgene S.A. en markedsverdi på $229.39M. Dette gjør Transgene S.A. til det 17440th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Transgene S.A. fra 2008 til 2026
TNG sammenlignet med topp 5 mest populære stocks
